Ipamorelin: mechanism, evidence, and how it's actually dosed

Last updated 2026-07-24

What is ipamorelin and how does it work?

Ipamorelin is a synthetic peptide made of five amino acids, classified as a growth hormone secretagogue. It binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, which triggers a pulse of growth hormone release from the pituitary gland. It doesn't add GH directly. It tells your own pituitary to release more of what it already makes. The original characterization paper, published in the European Journal of Endocrinology in 1998, described ipamorelin as "the first selective growth hormone secretagogue," distinguishing it from earlier compounds in the same family (GHRP-6, GHRP-2, hexarelin) that also stimulated cortisol and prolactin release as a side effect ^[1]. Selectivity is the whole pitch here: in animal and early human work, ipamorelin produced GH pulses without the broader hormonal noise that older secretagogues caused ^[1][2]. Chemically, ipamorelin was one of a series of GH-releasing peptides developed and patented in the late 1990s, described in two companion medicinal chemistry papers from 1998 that mapped out the structure-activity relationships behind its potency and receptor selectivity ^[2][3]. A follow-up paper in 2001 describes hybrid compounds combining ipamorelin's backbone with a separate secretagogue scaffold (NN703), aimed at improving potency further ^[4]. None of that chemistry work was conducted in patients being treated for a condition. It's early-stage pharmacology, useful for understanding mechanism, not for making clinical promises.

What does the human evidence actually show?

The human data on ipamorelin is thinner than the internet chatter suggests. The 1998 European Journal of Endocrinology study is the foundational human paper, and a separate pharmacokinetic-pharmacodynamic modeling study published in Pharmaceutical Research in 1999 characterized how ipamorelin behaves in human volunteers after dosing, describing the relationship between plasma concentration and GH release over time ^[5]. A nasal absorption pharmacokinetics paper from 1998 (Xenobiotica) looked at how ipamorelin and related peptidyl secretagogues are absorbed by different routes, relevant background for anyone comparing injectable vs. nasal delivery, though nasal ipamorelin isn't a mainstream clinical route today ^[6]. The most clinically interesting human trial is a 2014 randomized, controlled proof-of-concept study in bowel resection patients, published in the International Journal of Colorectal Disease, testing ipamorelin against postoperative ileus (the temporary bowel paralysis that follows abdominal surgery) ^[7]. That trial is worth flagging because it's a genuine randomized controlled human trial, not a rat study or a mechanism paper, and it's testing a completely different application than the muscle-and-fat-loss narrative that dominates fitness forums. A 2026 narrative review in the American Journal of Sports Medicine on injectable peptide therapy, aimed at orthopaedic and sports medicine physicians, and a companion 2026 review in JBJS Reviews on injectable peptides in sports medicine, both treat GH secretagogues including ipamorelin as an evolving area worth physician awareness, not as an established standard of care ^[8][9]. A 2026 review in Sports Medicine (Auckland) specifically assessing safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance takes the same posture: interesting mechanism, insufficient trial-level human evidence for the performance claims attached to it ^[10]. If you're deciding whether to try ipamorelin peptide benefits for body composition specifically, know that the strongest human trial data you'll find is about ileus recovery after surgery, not fat loss.

What has ipamorelin been shown to do in animal studies?

Most of what's known about ipamorelin's downstream effects (bone, body fat, nitrogen balance) comes from rodent studies, and that distinction matters a lot when you're reading marketing copy that blurs it. A 1999 study in Growth Hormone & IGF Research found that ipamorelin induced longitudinal bone growth in rats ^[11]. A related 2001 study in the same journal reported that ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats, meaning it partly offset the bone-thinning effect of steroid treatment in that model ^[12]. A 2000 study in the Journal of Endocrinology found that ipamorelin, along with GHRP-6, increased bone mineral content in adult female rats ^[13]. On body composition, a 2001 paper in Biochemical and Biophysical Research Communications described GH-independent stimulation of adiposity by GH secretagogues, a finding worth sitting with because it complicates the simple "more GH equals less fat" story that gets repeated online ^[14]. A 2009 study on nitrogen balance and urea synthesis in steroid-treated rats looked at how GH and GH secretagogues affect protein metabolism during catabolic steroid exposure ^[15]. On glucose metabolism, a 2004 paper in Neuroendocrinology Letters examined the mechanism by which ipamorelin evokes insulin release from the pancreas in normal and diabetic rats ^[16], and a 2002 histopathology study looked at the somatotroph (GH-producing pituitary cell) response after chronic ipamorelin treatment in young female rats ^[17]. None of these are human trials. They tell you ipamorelin does something biologically real and reproducible in animal models. They do not tell you what dose, frequency, or duration would replicate that in a person, and anyone who tells you otherwise is filling a gap with forum lore, not data.

Does ipamorelin help with pain or gut motility?

Two separate lines of animal research point to ipamorelin having effects outside the GH-and-body-composition story most people search for, and they're worth knowing even though neither is an approved indication. A 2020 paper in the Journal of Experimental Pharmacology, titled "Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics," reported pain-reducing effects of ghrelin mimetics including ipamorelin in animal pain models ^[18]. Two other rodent studies, one in the Journal of Pharmacology and Experimental Therapeutics (2009) and one in the Journal of Experimental Pharmacology (2012), tested ipamorelin's efficacy against gastric dysmotility and postoperative ileus in rodent models, both finding it improved gut motility recovery after surgical injury ^[19][20]. That mechanistic thread is what led to the human trial in bowel resection patients mentioned above ^[7]. A 2024 study in Physiology & Behavior tested ipamorelin alongside anamorelin (a related ghrelin receptor agonist) in ferrets undergoing cisplatin chemotherapy, and found both compounds inhibited cisplatin-induced weight loss, with anamorelin additionally showing anti-emetic (anti-nausea) effects through a central mechanism ^[21]. This is chemotherapy-supportive-care research, a completely separate clinical lane from bodybuilding or anti-aging use, and it's a sign that ipamorelin's real research momentum right now is in gut motility and cachexia, not physique enhancement.

What is CJC-1295 and why is it stacked with ipamorelin?

CJC-1295 is a separate peptide, a growth hormone-releasing hormone (GHRH) analog, not a ghrelin receptor agonist like ipamorelin. It works on a different receptor in the same GH-release pathway. Because GHRH and ghrelin receptor agonists act on separate, complementary steps of the same pituitary release mechanism, combining a GHRH analog with a ghrelin mimetic is intended to produce a bigger GH pulse than either compound alone. That's the mechanistic rationale behind cjc 1295 ipamorelin stacking, and it is a real, defensible pharmacology argument, more than forum tradition. You'll also see "CJC-1295 with DAC" and "CJC-1295 no DAC" used interchangeably online, and they are not the same molecule. DAC (Drug Affinity Complex) is a modification that binds the peptide to albumin in the blood, extending its half-life from minutes to days. Ipamorelin CJC-1295 no DAC combinations are dosed more frequently because the no-DAC version clears faster, closer to ipamorelin's own short half-life, which is why paired dosing schedules for simple peptides cjc 1295 ipamorelin protocols usually specify the DAC status explicitly. There is no head-to-head randomized trial comparing ipamorelin alone against ipamorelin-plus-CJC-1295 in humans that we're aware of. The stacking rationale is mechanistic and reasonable, not clinically proven at the combination level. If a source tells you the stack is "proven synergistic," ask them for the trial. There isn't one yet.

How does ipamorelin compare to tesamorelin?

Tesamorelin is also a GHRH analog, related in mechanism to CJC-1295, and it's the one GH secretagogue in this general family with actual FDA approval, specifically for lipodystrophy (abnormal fat redistribution) in HIV patients. You can check any drug's approval status directly in Drugs@FDA, the FDA's own database [FDA Drugs@FDA]. Ipamorelin has no FDA-approved indication in the United States. Because tesamorelin has an approved indication and a real prescribing history, and ipamorelin has a strong receptor-selectivity profile but thinner human trial evidence, some prescribers pair them: tesamorelin's GHRH mechanism plus ipamorelin's ghrelin receptor mechanism, similar rationale to the CJC-1295 pairing, aimed at a broader, complementary GH pulse. This is the basis for tesamorelin ipamorelin blends, which is also the format this peptide is actually dispensed in: there is no standalone ipamorelin product on the market, and any legitimate source will only offer it as part of a compounded tesamorelin/ipamorelin combination, never as ipamorelin alone. For a fuller side-by-side on mechanism, evidence strength, and which one has an approved indication, see ipamorelin vs tesamorelin.

Is ipamorelin legal, and is it regulated as a drug?

Ipamorelin is not FDA-approved as a drug for any indication. It exists in a regulatory gray zone shaped by compounding law. Under 21 U.S.C. 353a, licensed pharmacies can compound drugs for individual patients under a prescription, and a related FDA framework governs which bulk substances compounders are legally allowed to use [21 U.S.C. 353a]. The FDA maintains two relevant lists under its compounding regulations: the 503A Bulks List (21 CFR 216.23), covering substances that can be compounded by traditional pharmacies for individual patients, and the 503B Bulks List (21 CFR 216.24), covering substances that outsourcing facilities can use for larger-batch compounding [21 CFR 216.23][21 CFR 216.24]. Whether a specific peptide like ipamorelin appears on either list, or has been nominated and rejected, changes over time, and the FDA's own nomination and evaluation page is the only reliable place to check current status [FDA bulk drug substances]. This is exactly why there's no standalone consumer ipamorelin product sold as a finished drug. What legitimate providers actually offer is a compounded tesamorelin/ipamorelin blend, prepared by a licensed pharmacy under a clinician's prescription, not an off-the-shelf peptide you order and inject on your own judgment. Anything sold outside that structure, research-chemical vials with no prescription, no clinical oversight, and no quality testing, is a different risk category entirely, and a 2018 study in Growth Hormone & IGF Research that analyzed black-market growth-promoting products found exactly the kind of quality and identity problems you'd expect from an unregulated supply chain ^[22].

What are the real safety concerns with ipamorelin?

The clean safety story around ipamorelin (selective GH release, minimal cortisol/prolactin effect) comes from the 1998 European Journal of Endocrinology characterization work ^[1], and it's a real and meaningful finding relative to older secretagogues. But selective in early pharmacology work is not the same as safety-established in long-term human use, because the human trial base for ipamorelin specifically is small and mostly short-duration. A metabolism study in Analytical Chemistry (2012) mapped how GH-releasing peptides including ipamorelin are broken down in the body, relevant to detection windows and to understanding clearance ^[23]. Separate work in Drug Testing and Analysis (2015) determined ipamorelin metabolites in human urine after nasal dosing, and a 2017 structure-activity relationship paper in the same journal covers the broader class of peptidic GH secretagogues from an anti-doping detection angle ^[24][25]. Ipamorelin is banned by anti-doping authorities as a GH-releasing peptide; if you're a tested athlete, this matters regardless of the mechanism argument. Worth knowing: a 2024 study in Animal Reproduction Science found that ipamorelin acetate affected the hypothalamic-pituitary-testicular axis in a cichlid fish model, a reminder that ghrelin receptor agonists interact with reproductive hormone regulation in at least some species, and that this pathway hasn't been ruled out as clinically relevant in humans either ^[26]. If you want the full rundown on documented and theoretical adverse effects, injection site reactions, water retention, appetite changes, and what's speculative versus reported, that's covered in detail on ipamorelin side effects.

How is ipamorelin actually dosed in practice?

There is no FDA-approved dosing regimen for ipamorelin, because there is no FDA-approved ipamorelin product. Doses referenced in the literature and in compounding pharmacy protocols are derived from the pharmacokinetic modeling work (the 1999 Pharmaceutical Research study) ^[5] and from clinical extrapolation, not from a large approved-label dosing trial. In practice, ipamorelin is short-acting; its effect on GH pulsing is transient, which is why protocols typically call for once or twice daily subcutaneous dosing, often timed around sleep or fasting windows to align with the body's natural GH pulse pattern. When paired with a longer-acting GHRH analog like CJC-1295 with DAC, dosing frequency for the GHRH component drops because DAC extends its half-life to days rather than minutes, while the ipamorelin component still needs more frequent dosing because it doesn't carry that modification. Because dosing is compounded and individualized rather than standardized by an approved label, exact numbers depend on the prescribing clinician, the specific blend concentration, and the patient's goals. If you want the actual number ranges used in current compounding practice, along with how tesamorelin/ipamorelin blend ratios change the math, see ipamorelin dosage and the cjc-1295 ipamorelin dosage calculator. Reconstitution technique also matters more than people expect: getting the diluent volume and storage right affects both potency and sterility, covered in reconstitute cjc ipamorelin.

Who is actually researching or using ipamorelin today, and for what?

Three fairly distinct populations show up in the recent literature. The first is orthopaedic and sports medicine, where a cluster of 2026 review papers, in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, the American Journal of Sports Medicine, and JBJS Reviews, treat GH secretagogues and other injectable peptides as an emerging category physicians need to understand for patient questions and anti-doping counseling, not as an established treatment pathway ^[27][8][9]. The second is aging and metabolic medicine. A 2026 review in the International Journal of Molecular Sciences covers therapeutic peptides across aesthetic, metabolic, and endocrine conditions broadly ^[28], and a 2026 review in Frontiers in Aging looks specifically at therapeutic peptides in gerontology, mechanisms relevant to healthy aging ^[29]. Ipamorelin peptides show up in both as part of the broader GH-axis story, alongside other secretagogues, rather than as a singularly proven agent. The third is hypogonadal male health. A 2020 review in Translational Andrology and Urology, titled "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males," makes the case that GH secretagogues have a role alongside testosterone therapy for body composition in men with low testosterone, distinct from testosterone replacement itself ^[30]. That's a genuinely different clinical argument than the generic "anti-aging peptide" framing you see in consumer marketing, and it's worth reading directly if that's your situation. Ipamorelin Co works from this same evidence base: dispensing follows a provider-reviewed protocol using a tesamorelin/ipamorelin blend prepared by a licensed compounding pharmacy partner, not a self-directed peptide purchase.

What's folklore vs. what's actually studied?

Here's a plain-language sort of what has real citations behind it and what's repeated because it sounds plausible. | Claim | Evidence status |

Frequently asked questions

What is ipamorelin used for?

Ipamorelin is a ghrelin receptor agonist studied for triggering pulsatile growth hormone release. Human research includes a 1998 selectivity study and a 2014 randomized trial in postoperative ileus recovery. Rodent studies also point to effects on bone density and body fat. It has no FDA-approved indication and is dispensed only as part of a compounded tesamorelin/ipamorelin blend.

Is ipamorelin the same as CJC-1295?

No. Ipamorelin is a ghrelin receptor agonist; CJC-1295 is a GHRH analog acting on a different receptor in the same pathway. They're often combined because the mechanisms are complementary, though no cited human trial has directly compared the combination against either compound alone.

What's the difference between CJC-1295 with DAC and without DAC?

DAC (Drug Affinity Complex) binds CJC-1295 to albumin in blood, extending its half-life from minutes to days. CJC-1295 no DAC clears faster and needs more frequent dosing, closer to ipamorelin's own short half-life, which is why the two are often scheduled together on a daily basis.

Can I buy standalone ipamorelin?

No legitimate source sells a standalone FDA-approved ipamorelin product because none exists. It's available only as a compounded tesamorelin/ipamorelin blend through a licensed pharmacy under a prescription. Products sold outside that structure fall into the unregulated black-market category, where a 2018 study found real quality and identity problems in growth-promoting compounds.

Is ipamorelin FDA-approved?

No. There is no ipamorelin product listed in Drugs@FDA, the FDA's official approved-drug database. It is used only through pharmacy compounding under 21 U.S.C. 353a, and its bulk-substance status for compounding is reviewed periodically by the FDA rather than fixed by an approval.

Does ipamorelin cause side effects like cortisol or prolactin spikes?

The 1998 European Journal of Endocrinology characterization study found ipamorelin produced GH release with minimal effect on cortisol and prolactin, unlike older secretagogues such as GHRP-6. That finding comes from early, small-scale human work, not a large long-term safety trial.

Does ipamorelin help with fat loss?

The clearest fat-related finding is a 2001 rodent study showing GH-independent stimulation of adiposity by GH secretagogues, a mechanistic finding, not a human fat-loss trial. No cited human RCT in the current evidence base measures body fat change from ipamorelin alone.

What is tesamorelin ipamorelin used for compared to ipamorelin alone?

Tesamorelin is FDA-approved for HIV-associated lipodystrophy and works as a GHRH analog. Combining it with ipamorelin pairs two complementary GH-release mechanisms. Since no standalone ipamorelin product exists, this blend is the actual dispensed form, not a marketing add-on.

Is ipamorelin banned in sports?

Ipamorelin falls under the broader category of GH-releasing peptides that anti-doping authorities prohibit. Detection method research, including 2015 urine metabolite studies and 2017 structure-activity work in Drug Testing and Analysis, exists specifically because these peptides are tested for in competitive sport.

How is ipamorelin dosed?

There's no FDA-approved dosing label. Compounding pharmacies dose it based on pharmacokinetic modeling research and clinical judgment, typically as subcutaneous injections once or twice daily, often paired with a GHRH analog. Exact amounts depend on the blend and prescriber; see a dedicated dosage guide for current ranges.

Does ipamorelin help with gut motility after surgery?

This is one of the better human-evidence use cases. A 2014 randomized controlled proof-of-concept trial in bowel resection patients tested ipamorelin against postoperative ileus, building on earlier rodent studies showing improved gastric motility recovery after surgical injury.

Is ipamorelin safe for long-term use?

Long-term human safety data is limited; most published human work is short-duration pharmacology or a single surgical-recovery trial. Reproductive-axis effects have shown up in at least one non-human animal model, so treat long-term use as an open question rather than settled.

What's the difference between ipamorelin and tesamorelin?

Tesamorelin is a GHRH analog with FDA approval for a specific condition (HIV lipodystrophy). Ipamorelin is a ghrelin receptor agonist with no FDA approval, studied mainly in animal models and a small number of human trials. They act on different receptors in the same GH-release pathway.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin was characterized as the first selective growth hormone secretagogue, with minimal effect on cortisol/prolactin versus older secretagogues, in a 1998 human study
2. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides in orthopaedics, including applications and challenges relevant to physicians
3. American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a physician-oriented primer on injectable peptide therapy in orthopaedic and sports medicine
4. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance
5. International Journal of Molecular Sciences, 2026 (PMID 42123471): Covers therapeutic peptides across aesthetic, metabolic, and endocrine conditions including effects and safety
6. Frontiers in Aging, 2026 (PMID 42021992): Reviews therapeutic peptide mechanisms and applications relevant to healthy aging in gerontology
7. Translational Andrology and Urology, 2020 (PMID 32257855): Discusses the role of growth hormone secretagogues in managing body composition in hypogonadal males, distinct from androgen receptor therapy
8. Physiology & Behavior, 2024 (PMID 39043357): Ipamorelin and anamorelin inhibited cisplatin-induced weight loss in ferrets, with anamorelin also showing central anti-emetic effects
9. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Ghrelin mimetics including ipamorelin attenuated visceral and somatic nociception in animal pain models
10. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes the development of novel orally active growth hormone secretagogues including early ipamorelin chemistry
11. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in rats
12. Histology and Histopathology, 2002 (PMID 12168778): Chronic ipamorelin treatment affected somatotroph response in vitro in young female rats
13. Pharmaceutical Research, 1999 (PMID 10496658): Pharmacokinetic-pharmacodynamic modeling of ipamorelin characterized its GH-release behavior in human volunteers
14. Growth Hormone & IGF Research, 2009 (PMID 19231263): Studied GH and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats
15. Analytical Chemistry, 2012 (PMID 23101768): Mapped the metabolism of growth hormone releasing peptides including ipamorelin
16. International Journal of Colorectal Disease, 2014 (PMID 25331030): A randomized controlled proof-of-concept trial tested ipamorelin for management of postoperative ileus in bowel resection patients
17. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of new growth-promoting black market products found quality and identity issues in unregulated supply
18. Xenobiotica, 1998 (PMID 9879640): Evaluated the pharmacokinetics of ipamorelin and related peptidyl GH secretagogues, emphasizing nasal absorption
19. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Ipamorelin improved gastric dysmotility in a rodent model of postoperative ileus
20. Journal of Pharmacology and Experimental Therapeutics, 2009 (PMID 19289567): Ipamorelin showed efficacy in a rodent model of postoperative ileus
21. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats
22. Drug Testing and Analysis, 2015 (PMID 25869809): Determined ipamorelin metabolites in human urine after nasal administration, relevant to anti-doping detection
23. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Describes a series of highly potent growth hormone-releasing peptides derived from ipamorelin
24. Bioorganic & Medicinal Chemistry Letters, 2001 (PMID 11459660): Describes hybrid growth hormone secretagogues combining NN703 and ipamorelin structures
25. Animal Reproduction Science, 2024 (PMID 38996787): Ipamorelin acetate influenced the hypothalamic-pituitary-testicular axis in a cichlid fish model
26. Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increased bone mineral content in adult female rats
27. Neuro Endocrinology Letters, 2004 (PMID 15665799): Examined the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats
28. JBJS Reviews, 2026 (PMID 42160466): A structured narrative review of injectable peptides in sports medicine covering evidence, safety, and anti-doping implications
29. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): Found GH-independent stimulation of adiposity by GH secretagogues in an animal model
30. Drug Testing and Analysis, 2017 (PMID 26811125): Reviews the structure-activity relationship for peptidic growth hormone secretagogues relevant to detection
31. 21 U.S.C. 353a, pharmacy compounding: Establishes the legal basis for licensed pharmacy compounding of drugs like ipamorelin under a patient prescription
32. 21 CFR 216.23, the 503A Bulks List: Lists bulk drug substances that traditional compounding pharmacies may legally use for individual patients
33. 21 CFR 216.24, the 503B Bulks List: Lists bulk drug substances that outsourcing facilities may use for larger-batch compounding
34. FDA, bulk drug substances used in compounding under section 503A: FDA's current framework and status page for evaluating bulk substances nominated for compounding use
35. Drugs@FDA, FDA-approved drug products database: Confirms there is no FDA-approved standalone ipamorelin drug product listed